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Lung cancera b s t r a c t
Purpose: A major burden of introducing an online daily adaptive proton therapy (DAPT) workflow is the
time and resources needed to correct the daily propagated contours. In this study, we evaluated the dosi-
metric impact of neglecting the online correction of the propagated contours in a DAPT workflow.
Material and methods: For five NSCLC patients with nine repeated deep-inspiration breath-hold CTs, pro-
ton therapy plans were optimised on the planning CT to deliver 60 Gy-RBE in 30 fractions. All repeated
CTs were registered with six different clinically used deformable image registration (DIR) algorithms to
the corresponding planning CT. Structures were propagated rigidly and with each DIR algorithm and ref-
erence structures were contoured on each repeated CT. DAPT plans were optimised with the uncorrected,
propagated structures (propagated DAPT doses) and on the reference structures (ideal DAPT doses), non-
adapted doses were recalculated on all repeated CTs.
Results: Due to anatomical changes occurring during the therapy, the clinical target volume (CTV) cover-
age of the non-adapted doses reduces on average by 9.7% (V95) compared to an ideal DAPT doses. For the
propagated DAPT doses, the CTV coverage was always restored (average differences in the CTV V95 < 1%
compared to the ideal DAPT doses). Hotspots were always reduced with any DAPT approach.
Conclusion: For the patients presented here, a benefit of online DAPT was shown, even if the daily opti-
misation is based on propagated structures with some residual uncertainties. However, a careful (offline)
structure review is necessary and corrections can be included in an offline adaption.
 2021 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 159 (2021) 136–143 This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Online daily adaptive proton therapy (DAPT), specifically an
optimization directly before the delivery of each fraction, allows
for fast reactions to anatomical changes during the treatment
course. Currently, similar online adaptive radiotherapy workflows
are clinically implemented in several centers with MRI-linacs
[1,2], MRI-Cobalt machines [3–5] or standard linacs with Cone-
beam CTs (e.g. Varian Ethos [6]). One of the main challenges is to
define the contours on the daily image. This has to be performedas quickly as possible, while guaranteeing a high accuracy. Typi-
cally, daily contours are generated either by propagation of the
planning contours [7,8] after having deformed the daily to the
planning image, or by automatic segmentation of the daily image
[9–11]. The contour propagation process takes in general less than
a minute, whereas for an automatic segmentation about 5–10 min-
utes are necessary [12]. Additionally, after the daily volumes have
been generated, medical doctors need typically approximately 15
minutes to inspect and correct contours of the tumour and the
organs-at-risk (OARs) in proximity to the target [2,3]. It is recog-
nised, that the availability of daily contours is nowadays the main
bottleneck for the widespread use of online adaption.
Non-small cell lung-cancer (NSCLC) tumours are surrounded by
dose-sensitive OARs, such as the lung, heart or oesophagus. There-
fore, the improved normal tissue sparing offered by proton therapy
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anatomy of these patients is typically changing during the treat-
ment course and the breathing motion makes an irradiation with
protons challenging. Motion mitigation techniques such as rescan-
ning [17], gating [13], tracking [18], 4D-optimisation [19,20] or
deep-inspiration breath-hold (DIBH) [21] can handle the latter,
while for the former fast online daily plan adaption can restore
the target coverage [22,23]. Previous studies showed that the dose
degradation caused by changing anatomy is more severe than that
caused by intra-fractional changes (patients treated in free breath-
ing with rescanning) and makes treatment plan adaption necessary
[24].
At PSI an online DAPT workflow has recently been developed
[25] and successfully tested for non-deforming anatomies on a
phantom [26]. In the DAPT workflow a daily CT is acquired in treat-
ment position, contours are transferred and a plan is reoptimised
online [27], followed by a fast clinical and measurement-free
physical quality assurance [28]. After the delivery, the dose is
reconstructed on the planning CT [29,30]. One of the main require-
ments to deliver an online adaptive workflow is speed. Ideally the
time-span between the acquisition of the daily image and the start
of the delivery of the treatment should be comparable to the time-
span of the standard delivery. This can only be achieved if no
human corrections are done during the process, including no
additional correction of the daily structures. Although automatic
segmentation decreases the time required for online contour defi-
nition, limiting the human correction will inevitably result in daily
structures with some residual uncertainties [31]. The impact of
such uncertainties on the dose distributions is however still
unknown.
In this study, the dosimetric impact of optimizing a daily plan
on uncorrected propagated structures is investigated. In particular,
we compare the dosimetric effects of propagated DAPT doses (opti-
mised with rigidly and DIR propagated structures) to non-adapted
doses and ideal DAPT doses (optimized on structures contoured by
a radio-oncologist).Materials and methods
Patient data and treatment plans
For this retrospective study, a subset of five NSCLC patients with
different patient geometries and a complete dataset composed of
one planning and nine repeated CTs (three CTS in consecutive
DIBHs acquired on day of 2nd, 16th and 31st treatment fraction,
respectively) were selected from a dataset of locally advanced
NSCLC patients (median age 67 years, range 46–80) treated
between 2012 and 2013 with photon therapy [32]. All CTs were
acquired in voluntary visually guided DIBH. Although multiple
CTs were acquired on the same day, each repeated CT was, for
the purpose of this study, considered to represent one independent
daily patient anatomy. Structures (gross tumour volume (GTV),
clinical target volume (CTV) and relevant OARs) were contoured
by the same experienced radiation oncologist on all ten CTs per
patient. Intensity modulated proton therapy treatment plans with
60 Gy-RBE (RBE = 1.1) in 2 Gy-RBE per fraction were optimised on a
planning target volume (PTV), which was generated by a homoge-
neous extension of the CTV by 5 mm [33]. Plans consisting of three
individually selected fields [24,33–35] were optimised using an in-
house developed planning system and analytical dose calculation
algorithm [27,36].Image registrations
The repeated CTs were first rigidly registered to the planning CT
with focus on the vertebra using Velocity (Varian Medical Systems,137Palo Alto, USA). Then, six different DIRs were applied (two open
source Demons and B-splines algorithms [37,38] from Plastimatch
and four commercial algorithms one from Velocity [39], one from
Mirada (Mirada Medical, Oxford, UK) [40] and two, Anaconda
[41] and Morfeus [42], from RayStation (RaySearch Laboratories,
Stockholm, Sweden)). All algorithms, except Morfeus, have been
used without a focus region. For Morfeus, the lung contours were
used as a controlling region of interest. The details about the DIR
algorithms used in this study are given in the supplement.Calculation of DAPT and non-adapted doses
A scheme of the workflow used in this paper is shown in Fig. 1.
The planning structures (target and OARs) of all five patients were
propagated to the corresponding repeated CTs with rigid registra-
tion and with each of the six DIR algorithms using Plastimatch. The
PTV for the DAPT plans was generated from each propagated CTV
by expanding it by 5 mm, as done for the planning CT. Propagated
DAPT doses were optimised based on each propagated structure set
(DIR DAPT doses and rigid DAPT doses), ideal DAPT doses were opti-
mised based on the reference structures defined by the medical
doctor on each repeated CT. This resulted, for each repeated CT,
in eight dose distributions optimised on different daily structures.
Additionally, a worst-case non-adapted dose was generated by
recalculating the treatment plan on the repeated CTs.Evaluation
The non-adapted, propagated DAPT and ideal DAPT doses were
evaluated on each repeated CT using the reference structures
defined by the medical doctor. The CTV V95, D2 and the V20 of
both lungs excluding GTV of the non-adapted doses and the propa-
gated DAPT doseswere compared to the ideal DAPT doses (optimised
on the reference structures). Additionally, the structures were
reviewed visually, and the overlap (the percentage of the reference
structure covered by the propagated structure) of the propagated
CTV and the reference CTV evaluated in Matlab (MathWorks, Natic,
USA).
Results
As expected, a visual review of the different propagated CTVs
showed substantial differences. Fig. 2 shows an example slice of
the CTVs propagated with the different algorithms and the refer-
ence structure manually contoured on the CT at the end of the
treatment. The overlap between the propagated structures with
the reference structures (table 1) is on average between 79.1% (pa-
tient 2) and 93.8% (patient 4). For example, for patient 1 the CTV
shift and shrinkage between the rigid (blue) and the reference
structure defined on this CT (green) is not followed completely
by the CTVs propagated with the different DIR algorithms. For
other patients and other slices of these patients however, all the
structures agree.
The dosimetric impact of optimising the plan based on the
uncorrected propagated structures is shown in Fig. 3. The differ-
ences between CTV V95 and D2 of the non-adapted doses, DIR DAPT
doses and rigid DAPT doses to the ideal DAPT doses are shown. If the
DAPT plan was optimised on the propagated structures with DIR
(black), the CTV V95 differed on average by 0.04%, compared to
the ideal DAPT doses. With the rigid structure propagation (blue)
the differences were only slightly larger (0.6%). However, for the
non-adapted doses (red), the CTV V95 was reduced by an average
of 9.7% and the hotspots (e.g. CTV D2) increase severely (up to
12.8% higher for patient 2). DAPT reduced hotspots, independently
from the accuracy of the structures used for optimization. For
patient 4 larger differences between the ideal DAPT doses and the
Fig. 1. Scheme of the workflow. On the planning CT, structures and an initial treatment plan was defined for all 5 patients. For each patient, nine repeated CTs were available.
The planning structures were transferred to the repeated CTs using 6 different DIRs and a rigid registration. Additionally, new reference structures were defined on each
repeated CT by a medical doctor. Propagated DAPT doses were re-optimised using the structures propagated rigidly (rigid DAPT doses) and with each DIR algorithm (DIR DAPT
doses). Ideal DAPT doses were optimized on the reference structures. Non-adapted doses were obtained by recalculating the initial plan on the repeated CTs.
DIR for strucutre propagation in adaptive proton therapypropagated DAPT doses (DIR and rigid) are visible. For this patient
lymph nodes have shrunk substantially during the therapy
(Fig. 4), which was not completely transformed by the propagated
structures. Consequently, the target volume from the reference
structure set was smaller than the one from the propagated
structures.
The absolute dose to the OARs, for example the V20 of the lung
excluding GTV, is mainly depending on the tumour location. The
effect of DAPT is however different (Fig. 3c). For some patients with
large tumour changes, not adequately represented through the
propagated structures, larger difference between the ideal DAPT
doses and the propagated DAPT doses are detected. For example,
the V20 of the lung excluding GTV of patient 4 increased in average
by 3.3% (DIR DAPT doses) or 3.5% (rigid DAPT doses) compared to the
ideal DAPT doses. With a non-adapted approach however, the V20
for this patient would be even higher (5.0% difference compared
to the ideal DAPT dose). For other patients (e.g. patient 2) using
the reference structures for DAPT optimization slightly increased
the dose to the lung (up to 2% compared to rigidly propagated
structures).
In Fig. 4, the difference between the non-adapted dose, an
example of a propagated DAPT dose and the ideal DAPT dose from
a CT at the end of treatment is shown. The non-adapted doses
show severe hotspots or dose degradations in the target. However,
also for the patients with a large target variation (for example
patient 1 and 4 in Fig. 4), there is a clear advantage in performing
a daily adaptive treatment, instead of using the ‘‘worst-case” non-
adaptive approach (reduction of hotspots, target coverage for
patient 2).ig. 2. Examples of the CTV structures propagated rigidly (blue) or by the different
IRs (yellow) and the reference structures defined by a doctor (green) on a repeated
T from the end of the treatment. The structures differ between each other. For
xample the tumour shrinkage of patient 4 defined by the radiation oncologist is
ot following the propagated structures.Discussion
In this study, we show that DAPT is beneficial for NSCLC
patients treated in DIBH, even if the online daily optimisation is
based on uncorrected, propagated structures. The target coverage
is only slightly affected (CTV V95 difference <1%) if the daily plan
is optimized based on the uncorrected propagated structures com-
pared to the ideal DAPT plan (optimised on the structures con-
toured by a radiation oncologist). If the treatment is not adapted
however, the target coverage is reduced (average CTV V95 differ-
ence 9.6%) and large hotspots appear (up to 140%), which are
always reduced with DAPT (Figs. 3 and 4). For some patients how-
ever, DAPT could be beneficial also for specific OARs compared to
no adaption and for some OARs a benefit of the ideal DAPT dose
over propagated DAPT doses was seen (Fig. 3c). These results are
in line with the findings of Qiao et al. [43], who reported that using138automatically segmented structures might facilitate the introduc-
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Fig. 3. Differences between the CTV V95 and the CTV D2 and the V20 of the lung
without GTV of the ideal DAPT doses, based on the reference structures defined by a
radiation oncologist, to the DIR DAPT doses (black), rigid DAPT doses (blue) and
non-adapted doses (red). The bars show the range and the box the average
difference over all DIRs and fractions. The bars for the rigid (blue) and non-adapted
(red) dose parameters contain nine data points (one from each repeated CT), the bar
of the DIR (black) dose parameter contains 54 data points (nine CTs times six DIR
algorithms per patient).
L. Nenoff, M. Matter, Enrique Javier Amaya et al. Radiotherapy and Oncology 159 (2021) 136–143It should be noted that the propagated CTVs (either rigidly or
with DIR) differ from the reference CTV contoured by the radiation
oncologist (Fig. 1, Table 1). This is especially noticeable in case of
major tumour changes during the course of therapy (patient 1
and 4, Fig. 2). For these patients, the lymph nodes and the primary
GTV shrank during the treatment course. Despite this residual vari-
ation in the structure, and independently from the structure prop-
agation method, DAPT showed a dosimetric improvement over a
non-adapted treatment.
Interestingly, we found no advantage for the target coverage or
OAR doses if the daily plan was optimized based on the deformable
instead of rigid contour propagation. For the lung without GTV
however, the ideal DAPT plan optimized on the reference struc-
tures would be beneficial for some patients. For the cases reported
here, the increase of dose to the OARs did not violate any pre-
scribed dose tolerances.
In clinical practice, if large anatomical changes are observed, the
plan would be adapted offline. Therefore, the completely non-
adapted scenario investigated in this study might overestimate
the effects of DAPT compared to a clinical scenario. Therefore,
the non-adaptive doses can be seen as a worst case scenario.
For this study, the structures defined by an experienced radia-
tion oncologist were used as reference. Although this is the clinical
approach used for offline adaption, it has some limitations. For
example, it has been shown that structures defined by different
medical doctors [44,45] and even by the same doctor at different
times differ between each other [45]. Additionally, the CTV was
based on the macroscopic GTV visible in each fraction. However,
it is debatable how to properly deal with shrinkage occurring dur-
ing treatment. Indeed, a shrinkage of the macroscopic tumour vol-
ume does not coincide per se with a reduction of the microscopic
spread and it is still unclear which is the minimum therapeutic
dose that has to be delivered to treat the microscopic spread
[46]. The LARTIA Trial reported promising results for adaptive ther-
apy with a reduced CTV for Stage III NSCLC tumour patients with
photon therapy [47]. Other studies, instead showed the risk of
under-dosing the remaining CTV [48]. Large clinical trials are
needed to establish a safe clinical practice of how to deal with
tumour shrinkage for NSCLC patients [46,49,50].
It is acknowledged that lung tumours are one of the most chal-
lenging indications for proton therapy. Besides intra-fractional
motion, the dose calculation in low-density lung tissue has large
uncertainties and large inter-fractional changes are expected to
occur [24,51–53]. Each of these challenges are discussed separately
in the following paragraphs.
Intra-fractional changes can be mitigated through rescanning
[17], gating [13], tracking [18], 4D-optimisation [19,20] or DIBH
[21]. Visually guided DIBH was the one simulated in this study.
We assumed that the entire treatment dose was delivered within
one breath-hold. This is however a simplification: the breath can
be held in a standard situation for around 20 to 30 seconds [33].
Thus, depending on the tumour size, it might take two to five
breath-holds to deliver a field. However, with current develop-
ments in controlled breath-hold [54], it is possible to hold the139breath up to several minutes. Combined with recent investigations
about decreasing delivery times [55], the delivery of the entire field
in future will be possible within one breath-hold. Additionally, pre-
Fig. 4. Example slice of the non-adapted dose, DIR DAPT dose and the ideal DAPT dose of a CT at the end of treatment for all patients. Reference CTV and PTV structures of this CT
are shown in red.
DIR for strucutre propagation in adaptive proton therapyvious studies have also shown a high reproducibility of DIBH for
NSCLC patients [32,56].
In this study, the dose was optimized with an analytical dose
calculation algorithm. In general Monte Carlo (MC) calculations
have smaller dose calculation uncertainties, especially in areas
with large density heterogeneities [57–60]. However, in online
DAPT, time is a critical factor and even with the fastest available
proton MC dose calculations [61–64], a full plan optimization takes
~5 min, while analytical algorithms reoptimise the plan within a
few seconds [27]. Additionally, the analytical algorithm used in140this study has been shown to compare favourably with full Monte
Carlo (TOPAS) dose calculations, with 97.7% and 91.9% of all voxels
agreeing within 5% and 3% for a variety of indications, including
lung [65] and the difference between the different dose calculation
algorithms were negligible compared to those caused by anatomi-
cal changes [22]. As such, the online dose optimisation will be done
with this analytical dose calculation algorithm. The workflow how-
ever could be extended with a fast MC dose recalculation before
the delivery of the new plan, which could run in parallel to the plan
QA and delivery preparation, such that a MC calculated dose would
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an offline QA with a log-file based MC dose reconstruction would
then be performed.
Inter-fractional changes can be addressed with adaption [24].
Because of the large and fast anatomical changes, NSCLC patients
might especially benefit from an adaptive workflow. The online
daily adaptive strategy followed in this study is similar to the stan-
dard workflow, including a daily planning CT, contour propagation,
a full reoptimisation and quality assurance of the treatment plan
each day. The biggest challenge in such an online DAPT workflow
is to have a structure set available on the daily CT, without requir-
ing additional time and resources. Currently, adaptive structures
are either propagated with one DIR algorithm, or segmented using
an auto-contouring tool. However, due to the intrinsic uncertain-
ties, with both approaches and independently from the used DIR,
the resulting daily structure set has to be corrected by a radiation
oncologist [9,12,66]. In an online adaptive workflow the time
required for manual corrections normally exceeds the time avail-
able in a high-throughput treatment. With this study, we showed
that such time-intensive online corrections are not always neces-
sary. The benefits of using a DAPT workflow are evident, even if
uncorrected, propagated structures are used for optimisation. To
ensure a fast online workflow, structure sets could be checked
online only for plausibility, before the daily DAPT plan is delivered.
After the delivery, however, a careful structure revision and correc-
tion are necessary. A full plan reoptimisation used in this study (a
new spot placement, constraint optimisation [27,28]) has the
advantage that it allows for an improved plan quality in case of
favourable anatomy and also works in the case of major anatomical
changes, where the simpler approach of restoring the dose on the
new anatomy independent from the daily structures [67] might
fail. As part of the offline quality assurance after the delivery, the
delivered DAPT dose can then be reconstructed from the delivery
logfile, using the daily CT and a MC dose calculation [30,68], as
in such an online workflow, no patient specific dose measurements
are possible. The daily DVHs should then be evaluated with these
offline corrected structures. If major differences between the deliv-
ered and the desired dose distributions and DVHs are found, these
could then be corrected for in a feedback loop during the next frac-
tion, in a similar way to that described by Matter et al [69]. Man-
ually corrected structures can be used as the reference for the
next fractions.
The calculated dose differences between non-adapted and DAPT
dose could translate into differences in the clinical outcome (tu-
mour control probability/normal tissue complication probability)
of the patient. The calculation of treatment outcome based on
treatment doses and with changing target structures is not a
straight forward process and was not the scope of this study. How-
ever, due to the small dose differences between the DAPT doses
optimized with different propagated structures the impact of the
structure propagation method is expected to be small. It has to
be noted that any outcome differences can only be calculated ret-
rospectively, as the dose differences with and without adaption
can only be calculated when the anatomical changes during treat-
ment are known (e.g. repeated CTs). Since the anatomical changes
are not known beforehand, a prediction of these differences like in
the Dutch model-based approach [70,71] is not possible.
For the structure propagation with rigid image registration, the
same rigid image registration was used. Even if applying a sepa-
rate, local rigid registration per propagated structure might
improve the rigid contour propagation for some structures (for
example the lung or the heart), this was not considered, as apply-
ing several image registrations would not be a realistic option in a
clinical workflow.
Finally, we would like to point out some limitations of our
study. First, only 5 patients were included. With this limited data141set we do not quantify the influence of structure propagation for
all NSCLC patients. For instance, the selected patients all had large
tumours and showed large anatomical changes during treatment,
leading to large dose distortions and can thus be considered as
worst-case examples. Nevertheless, as the results are consistently
showing that the online DAPT is beneficial for such patients even
if optimized on uncorrected propagated structures, this indicates
that for the online DAPT implementation it might be enough to
perform a fast online plausibility check of the propagated struc-
tures combined with a careful offline review. If major differences
appear (e.g. large target shrinkages), these can be included in an
offline adaption, as already done in the current clinical practice.
On the other hand, patients with little or no dose distortions due
to anatomical changes might not benefit equally from DATP. For
these patients the risk of errors in contour propagation has to be
re-assessed and other, offline adaptive strategies, where time
allows for a correction of propagated structures, might then be
more suitable. Second, the nine CTs of these patents were acquired
on only 3 days, but in this study they were used as independent
fractions. With this study, we did not aim at investigating the dif-
ference between inter- and intra- fractional anatomical changes, as
this has been done previously [24,32,72]. Instead, we wanted to
have as many CTs of different anatomies from the same patients
as possible. We acknowledged that for some CTs acquired on the
same day, anatomical variations are smaller that if repeated CTs
would have been acquired on consecutive days. Nonetheless,
repeated CTs from the beginning, mid and end of treatment were
included, thus ensuring that the anatomical variability of the entire
treatment was represented. Finally, we simulated the patients
image guided positioning with focus in the vertebra, with the sur-
rounding anatomy being affected by the breath-hold. Alternative
image guided positioning methods with focus on the PTV are often
used in clinics [31], if a soft tissue positioning device (e.g. in-room
CT or CBCT) is available [33]. For patient 5, we recalculated the
dose for each repeated CT with both alignment settings (target-
and vertebrae-based) and observed similar dose degradations
(e.g. CTV V95). Even if the dose degradation with the rigid registra-
tion might be overestimated for some patients, we saw large den-
sity changes in the beam path with both methods, and
consequently dose differences in the recalculated plans. The DAPT
plan will restore daily the initial plan quality, independently from
the registration method.
In conclusion, we have shown that for the patients investigated
here, an online DAPT workflow is beneficial compared to a non-
adapted treatment, even if based on uncorrected propagated struc-
tures. Daily manual recontouring on each repeated CT only gives a
small additional benefit for some patients and OARs. This suggests
that the single DAPT fraction could be optimized based on the
uncorrected propagated structures, after performing a daily plausi-
bility check of these propagated contours. A careful offline review
of the propagated structure is nonetheless always recommended.Declaration of Competing Interest
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